disodium;4-[(Z)-[tert-butyl(oxido)azaniumylidene]methyl]benzene-1,3-disulfonate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: disodium;4-[(Z)-[tert-butyl(oxido)azaniumylidene]methyl]benzene-1,3-disulfonate
• 化学式: C11H13NNa2O7S2
• 分子量: 381.3
• InChiKey: XLZOVRYBVCMCGL-BPNVQINPSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -5.77
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  160
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• Novel process for the preparation of alpha-(2-4-disulfophenyl)-n-tert-butylnitrone and pharmaceutically acceptable salts thereof
  申请人：——

  公开号：US20030069442A1

  公开（公告）日：2003-04-10

  An integrated process for preparing &agr;-(2,4-disulfophenyl)-N-tert-butylnitrone and its salts is disclosed in which N-tert-butylhydroxylamine acid addition salt is incompletely neutralised so as to leave catalytic amounts of acid and the neutralisation product is condensed with an appropriate aldehyde.

  本发明公开了一种制备α-(2,4-二磺基苯基)-N-叔丁基硝基自由基及其盐的集成过程，其中N-叔丁基羟胺酸盐的加酸反应未完全中和，以留下催化量的酸，中和产物与适当的醛缩合。
• NITRONE COMPOUNDS, PROCESS OF PREPARATION THEREOF, AND USE THEREOF IN MEDICAMENT MANUFACTURE
  申请人：Wang Yuqiang

  公开号：US20110034485A1

  公开（公告）日：2011-02-10

  The present invention provides novel nitrones, their preparation and use. The novel compounds have the following formula: I The compounds of the present invention have strong antioxidative activity, and are thrombolytic. These compounds can be used to treat and/or prevent diseases caused by overproduction of free radicals and/or formation of thrombus.

  本发明提供了新型的亚硝基甲酰亚胺，其制备和用途。这些新化合物的化学式为：I。本发明化合物具有强抗氧化活性和溶栓作用。这些化合物可用于治疗和/或预防由自由基过度产生和/或血栓形成引起的疾病。
• [EN] NOVEL PROCESS FOR THE PREPARATION OF alpha -(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF<br/>[FR] NOUVEAU PROCEDE DE PREPARATION DE alpha -(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES
  申请人：ASTRAZENECA AB

  公开号：WO2001051461A1

  公开（公告）日：2001-07-19

  An integrated process for preparing α-(2,4-disulfophenyl)-N-tert-butylnitrone and its salts is disclosed in which N-tert-butylhydroxylamine acid addition salt is incompletely neutralised so as to leave catalytic amounts of acid and the neutralisation product is condensed with an appropriate aldehyde.

  本发明揭示了一种制备α-(2,4-二磺酰基苯基)-N-叔丁基亚硝基和其盐的集成工艺，其中N-叔丁基羟胺酸盐被不完全中和，以留下催化量的酸，然后将中和产物与适当的醛缩合。
• [EN] NOVEL PROCESS FOR THE PREPARATION OF alpha -(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF<br/>[FR] NOUVEAU PROCEDE DE PREPARATION DE alpha -(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE ET DE SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CELLE-CI
  申请人：ASTRAZENECA AB

  公开号：WO2001051460A1

  公开（公告）日：2001-07-19

  A process for the preparation of α-(2-4-disulfophenyl)-N-tert-butylnitrone and pharmaceutically acceptable salts thereof by the reaction of the corresponding disulfophenyl aldehyde with N-tert-butylhydroxylammonium acetate is disclosed.

  本发明公开了一种制备α-(2-4-二磺酰基苯基)-N-叔丁基亚硝基甲酸盐及其药学上可接受的盐的方法，该方法是通过将相应的二磺酰基苯醛与N-叔丁基羟胺醋酸盐反应而得到的。
• Novel formulations of alpha-2,4-disulfophenyl-n-tert-butylnitrone
  申请人：——

  公开号：US20030181527A1

  公开（公告）日：2003-09-25

  Novel pharmaceutical formulations of &agr;-(2,4-disulfophenyl)-N-tert-butylnitrone and pharmaceutically acceptable salts thereof and the use of such formulations in the treatment of various diseases and conditions, especially stroke, are disclosed.

  本发明涉及一种新型药物制剂，包括α-(2,4-二磺基苯基)-N-叔丁基硝基酮及其药学上可接受的盐，并且这种制剂可用于治疗各种疾病和病况，特别是中风。